For the Patients

For Patients

At Eisai we strive to prioritise patients and their families through our focus to continually improve the benefits that health care can provide.

Below is a list of our medicines that are currently available in Australia. For further information on any of our products please access the Consumer Medicines Information (CMI) via the links below.

Please always ask your healthcare professional for advice regarding medicines.

Patients

Reporting Side Effects

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the Consumer Medicines Information document.

Adverse events may also be reported to Eisai Australia Ltd.
Safety_Australia@eisai.net
tel: +61 (03) 9832 9100

Oncology

  • Lenvima®

    lenvatinib
    CMI
  • Halaven®

    eribulin mesilate
    CMI
  • Gliadel®

    carmustine
    CMI

Neurology

  • Fycompa®

    perampanel
    CMI
  • Inovelon®

    rufinamide
    CMI
  • Dayvigo®

    lemborexant
    CMI
Lenvima® is a registered trademark of the Eisai Group, whose affiliate company in Australia is Eisai Australia Ltd, PO Box 33004, Melbourne VIC, 3004, Australia Halaven® is a registered trademark of the Eisai Group, whose affiliate company in Australia is Eisai Australia Ltd, PO Box 33004, Melbourne VIC, 3004, Australia Gliadel® is a registered trademark of the Eisai Group, whose affiliate company in Australia is Eisai Australia Ltd, PO Box 33004, Melbourne VIC, 3004, Australia Fycompa® is a registered trademark of the Eisai Group, whose affiliate company in Australia is Eisai Australia Ltd, PO Box 33004, Melbourne VIC, 3004, Australia Inovelon® is a registered trademark of the Eisai Group, whose affiliate company in Australia is Eisai Australia Ltd, PO Box 33004, Melbourne VIC, 3004, Australia Dayvigo® is a registered trademark of the Eisai Group, whose affiliate company in Australia is Eisai Australia Ltd, PO Box 33004, Melbourne VIC, 3004, Australia